341 related articles for article (PubMed ID: 7481234)
1. [Respective indications for hormone therapy, induction chemotherapy and adjuvant chemotherapy in breast cancer without clinically discernable distant metastases].
Roy JA; Piccart MJ
Rev Med Brux; 1995; 16(4):242-4. PubMed ID: 7481234
[TBL] [Abstract][Full Text] [Related]
2. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
[TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
[TBL] [Abstract][Full Text] [Related]
4. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy.
Gasparini G; Barbareschi M; Boracchi P; Verderio P; Caffo O; Meli S; Dalla Palma P; Marubini E; Bevilacqua P
Cancer J Sci Am; 1995; 1(2):131-41. PubMed ID: 9166466
[TBL] [Abstract][Full Text] [Related]
5. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
6. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
Monnier AM
Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
[TBL] [Abstract][Full Text] [Related]
7. Goserelin (Zoladex)--its role in early breast cancer in pre- and perimenopausal women.
Jonat W
Br J Cancer; 2001 Nov; 85 Suppl 2(Suppl 2):1-5. PubMed ID: 11900209
[TBL] [Abstract][Full Text] [Related]
8. [Breast carcinoma--adjuvant chemo- and hormone therapy].
Fey MF
Ther Umsch; 1998 Jul; 55(7):413-4. PubMed ID: 9702106
[TBL] [Abstract][Full Text] [Related]
9. Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer.
Toi M; Yamashiro H; Tsuji W
Breast Cancer; 2009; 16(3):207-18. PubMed ID: 19259765
[TBL] [Abstract][Full Text] [Related]
10. Current and future status of adjuvant therapy for breast cancer.
Coleman RE
Cancer; 2003 Feb; 97(3 Suppl):880-6. PubMed ID: 12548590
[TBL] [Abstract][Full Text] [Related]
11. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
Goss PE
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
[TBL] [Abstract][Full Text] [Related]
12. [Adjuvant therapy of breast cancer].
Semiglazov VF; Abzumanov AS; Bozhok AA; Ivanov VG; Ivanova OA; Barash NIu; Topuzov EE; Seleznev IK; Migmanova NSh; Popova RT; Nurgaziev KSh
Khirurgiia (Mosk); 2001; (5):52-60. PubMed ID: 11505673
[No Abstract] [Full Text] [Related]
13. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
Mouridsen HT; Robert NJ
Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
[TBL] [Abstract][Full Text] [Related]
14. [Questions and answers on adjuvant systemic therapy in breast carcinoma].
Fey MF; Castiglione-Gertsch M
Ther Umsch; 1996 Nov; 53(11):839-46. PubMed ID: 8984689
[TBL] [Abstract][Full Text] [Related]
15. [Effectiveness of adjuvant systemic therapy in organ preserving treatment of pT1-2N0M0 breast cancer].
Semiglazov VF; Kanaev SV; Bugrova IL; Vlasov AN
Vopr Onkol; 1999; 45(5):516-9. PubMed ID: 10629708
[TBL] [Abstract][Full Text] [Related]
16. [Recent advance in adjuvant therapy for breast cancer].
Shimizu C; Watanabe T
Gan To Kagaku Ryoho; 2002 Dec; 29(13):2458-69. PubMed ID: 12506467
[TBL] [Abstract][Full Text] [Related]
17. Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?
Tang SC
Cancer Invest; 2008 Jun; 26(5):481-90. PubMed ID: 18568770
[TBL] [Abstract][Full Text] [Related]
18. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
19. Systemic adjuvant therapy for breast cancer.
Reed EC
Nebr Med J; 1996 Mar; 81(3):48-50. PubMed ID: 8907820
[TBL] [Abstract][Full Text] [Related]
20. A review of the BIG results: the Breast International Group 1-98 trial analyses.
Doughty JC
Breast; 2008 Jan; 17 Suppl 1():S9-S14. PubMed ID: 18279765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
